Clinical Trials Logo

Leishmaniasis, Cutaneous clinical trials

View clinical trials related to Leishmaniasis, Cutaneous.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05332093 Active, not recruiting - Clinical trials for Cutaneous Leishmaniases

Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia

SpatialCL
Start date: March 21, 2022
Phase:
Study type: Observational [Patient Registry]

Cutaneous leishmaniasis manifestations range from self-healing localized skin ulcers/nodules to diffusely spread chronic lesions. Knowledge on the host-parasite interactions underpinning the different clinical presentations is scarce, in particular for L. aethiopica infections where disease can be extremely severe. Our aim is to define differences in skin immune responses and parasite virulence in CL patients at single cell/parasite level and how it underpins the different clinical presentations (localised, mucocutaneous and diffuse), by producing the first spatially-resolved 'ecological' map of the lesions.

NCT ID: NCT04515186 Active, not recruiting - Clinical trials for Cutaneous Leishmaniases

Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World

Start date: January 26, 2021
Phase: Phase 3
Study type: Interventional

This study evaluates if the combination of thermotherapy (one application, 50⁰C for 30") and 3 weeks of miltefosine is safe and have a comparable cure rate with the current recommended first line treatments comprising meglumine antimoniate for 3 weeks for the treatment of uncomplicated cutaneous leishmaniasis cases in the New World.

NCT ID: NCT02530697 Active, not recruiting - Leishmaniasis Clinical Trials

The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil

Start date: August 2015
Phase: Phase 2
Study type: Interventional

Mucocutaneous leishmaniasis is endemic in the central region of Brazil and other countries worldwide. The standard treatment with meglumine antimoniate has a high rate of important adverse effects. This interventional study consists in a randomized clinical trial to access efficacy and safety of the association of miltefosine and pentoxifylline compared to meglumine antimoniate and pentoxifyline.